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Background and Objectives. Storage pool diseases
(SPD) are heterogeneous disorders associated with an
abnormal presence of intraplatelet granules, which cause
mild to moderate bleeding diathesis. We investigated
signaling through tyrosine phosphorylation of proteins
occurring in platelets with total or partial absence of
dense- and α-granules in response to activation.
Design and Methods. We included a patient with severe
δ-SPD, a patient with severe α-SPD or gray platelet syn-
drome, and six patients with partial deficiency of dense
or α-granules. SPD was confirmed by electron
microscopy evaluation of platelet ultrastructure. Platelet
function was evaluated by bleeding time determination
and conventional aggregometry. Platelet suspensions
were activated with collagen and thrombin to analyze
changes in tyrosine phosphorylation of proteins by elec-
trophoresis and Western-blotting.
Results. Bleeding times were prolonged in all the patients
included. Aggregation responses were slightly decreased
in δ-SPD and normal in the rest of patients. Tyrosine
phosphorylation in platelets from patients with partial
forms of SPD was equivalent to that observed in control
platelets, absent in response to collagen and thrombin
activation in δ-SPD, and deficient only to thrombin acti-
vation in α-SPD.
Interpretation and Conclusions. Tyrosine phosphoryla-
tion of proteins in activated platelets is highly dependent
on the substances contained in the dense-granules and
moderately dependent on those contained in the α-gran-
ules. A minimum amount of intraplatelet granules
ensures signaling through tyrosine phosphorylation of
proteins.
©2002, Ferrata Storti Foundation
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Hereditary storage-pool diseases (SPD) areplatelet specific-granule deficiencies with awide range of clinical and laboratory mani-
festations.1-3 Dense-granule deficiencies or δ-SPD
may be isolated or associated with other conditions
such as tyrosinase-positive oculocutaneous alb-
inism in the Hermansky-Pudlak syndrome. Gray
platelet syndrome (GPS), the main manifestation of
α-granule deficiency, shows the typical degranu-
lated platelets and thrombocytopenia. Mixed forms
of dense- and α- granule deficiencies, and partial
granule deficiencies of all types of SPD can also be
seen. Mild to moderate bleeding is the main clini-
cal manifestation of SPD. Aggregometry usually
shows a typical pattern in δ-SPD including lack of
a second wave when the platelets are stimulated by
ADP or epinephrine, and a general decrease when
stimulated by low doses of collagen. On the other
hand, aggregometry is variably affected in gray
platelet syndrome, and in partial forms of SPD, but
in some cases no defect can be demonstrated.
Platelet signal transduction is a complex mecha-
nism initiated when a receptor interacts with its
agonist, and results in several cellular responses
including dense- and α-granule release, and throm-
boxane A2 production.4 Coagulation factors and
inhibitors, adhesion molecules and growth factors
are the main α-granule proteins secreted,5 where-
as dense-granules release adenine nucleotides and
serotonin,6,7 which cause activation of other
platelets, specially co-operating with stronger acti-
vators such as thromboxane. Phosphoinositide
hydrolysis and arachidonate metabolism pathways,
G protein interactions, intracellular Ca2+ mobiliza-
tion, Ras and MAPK activation, cAMP formation,
and protein phosphorylation are the main mecha-
nisms involved in intraplatelet signaling and its reg-
ulation. When platelet activation occurs, a large
number of tyrosine kinases become active. Some of
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them are receptors for extracellular ligands, and
others are non-receptors such as Src, and Syk. In
early stages of activation a marked increase in phos-
phorylation of tyrosine residues occurs in several
cellular proteins including tyrosine kinases them-
selves and their substrates. Some tyrosine kinases
are activated by agonists independently of the
aggregation, such as Src and Syk, whereas others,
like FAK, become active during aggregation.8 It is
believed that tyrosine phosphorylation may regu-
late its target protein causing a conformational
change, or may provide a binding site for specific
domains present in other proteins (SH2 or PTB
domains). The precise roles of tyrosine kinases and
their specific substrates in platelet function are cur-
rently under investigation.
Protein phosphorylation in tyrosine residues has
only been studied in limited cases of SPD including
patients with Hermansky Pudlak syndrome,9 and gray
platelet syndrome,10 and in platelets from mice and
black cattle with Chediak-Higashi syndrome.11,12 In
order to contribute to the knowledge of the rela-
tionship between protein phosphorylation and
platelet release mechanisms, we analyzed tyrosine
phosphorylation of proteins in platelets from a group
of patients suffering from different types of SPD.
Design and Methods
Patients
Our study was carried out in accordance with the
principles of the Declaration of Helsinki. Informed
consent was obtained from all the participants.
Eight patients with SPD were enrolled in the study:
1 with severe platelet deficiency of dense-gran-
ules (δ-SPD), 1 with severe deficiency of α-gran-
ules (α-SPD) or gray platelet syndrome, and 6 with
a partial deficiency of dense- or α-granules (δ/α-
SPD). The diagnosis of the disease was established
by clinical and laboratory findings including
platelet granule ultrastructural evaluation. von
Willebrand’s disease and other non-platelet pri-
mary hemostatic defects were excluded, as were
kidney, liver, and myelodysplastic disorders.
All subjects included in our study were carefully
interviewed to exclude any possible intake of drugs
known to affect platelet function in the 10 days
preceding our investigations.
Experimental design 
Platelet function was evaluated by measuring the
bleeding time, and by standard aggregometric tech-
niques. Dense- and α-granule deficiencies were
established by transmission electron microscopy.
Signal transduction processes occurring through
tyrosine phosphorylation were also investigated in
platelets activated in suspension by two different
agonists, collagen and thrombin. Blood samples
from healthy volunteers were processed in parallel.
Platelet function
The bleeding time was measured by the Ivy
method13 and was considered normal up to 9 min-
utes. Whole blood was obtained by venipuncture
and anticoagulated with citrate-phosphate-dex-
trose (100 mM sodium citrate, 16 mM citric acid,
18 mM sodium hydrogen phosphate and 130 mM
dextrose) (at a final citrate concentration of 19
mM). Platelet-rich plasma (PRP) and platelet-poor
plasma (PPP) samples were obtained by centrifu-
gation of citrated blood samples at 200×g for 10
minutes, or at 800 × g for 20 minutes, respective-
ly, at 22°C. Aggregation studies were carried out
under stirring conditions in a Hitachi-Aggrecorder
aggregometer. Samples of PRP were placed in 6
mm-wide siliconized cuvettes. Platelet counts were
normalized to the same value (2×105 platelets/µL).
The minimum and maximum amplitudes of the
recorder were adjusted with PRP (0% transmission)
and PPP (100% transmission), respectively. Arachi-
donic acid (1.2 mM), ADP (4 µM), collagen (2.5
mg/mL), epinephrine (10 µM) and ristocetin (1
mg/mL) were used as inductors, under stirring.
Results were expressed as percentages of maxi-
mum aggregation obtained after 5 min of stimu-
lation.14
Ultrastructural studies
Peripheral venous blood was collected directly in
1.25% glutaraldehyde in White’s buffer saline,
without any anticoagulant, as previously
described.3 Briefly, after the fixed PRP preparation,
a platelet pellet was obtained and post-fixed in 1%
osmium tetroxide in White’s saline. Specimens
were then dehydrated in a series of graded alcohols
and embedded in Epon 812 following standard
methods. The ultrathin sections were stained with
uranyl acetate and lead citrate before being exam-
ined in a transmission electron microscopy at 80 Kv
accelerating voltage. Using computer-assisted
morphometry, the size and shape of the platelets
were measured as were the size and number per
platelet area (number/µm2) of the dense- and α-
granules. Other intraplatelet structures, such as the
open canalicular system (OCS), mitochondria, lipid
droplets, and glycogen aggregates were also mea-
sured. Ultrastructural morphologic features of the
above and other structures, such as the dense
tubular system (DTS), were included in the analy-
sis. Morphologic and morphometric results were
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compared with those obtained in a group of 15
healthy individuals. The dense- and α-granule
measurements were expressed as a percentage of
the control values.
Activation of platelet suspensions
Platelets were isolated from PRP, at 800×g for 20
minutes, and washed twice with equal volumes of
citrate-citric acid-dextrose (93 mM sodium citrate,
7 mM citric acid and 140 mM dextrose), pH 6.5,
containing 5 mM adenosine and 3 mM theo-
phylline.15 The final pellet was resuspended in Han-
ks' balanced salt solution (136.8 mM NaCl, 5.4 mM
KCl, 0.2 mM MgSO4×7H2O, 0.6 mM Na2HPO4, 0.4
mM KH2PO4, 0.5 mM MgCl2x6H2O, 1.3 mM CaCl2)
and platelet counts adjusted to 1.2×106
platelets/µL. Aliquots of platelets suspensions were
kept at 37°C for 20 minutes before activation.
Activation of platelet suspensions with purified
type I collagen or thrombin was carried out under
stirring conditions in the aggregometer. Aliquots
were activated with either 20 µg/mL of purified type
I collagen (Chrono-Par, Chrono-Log Co, Haver-
town, PA, USA) or 0.1 U/mL of thrombin (Sigma
Chemical C, St. Louis, USA) for 90 seconds. Platelet
aggregation was recorded and results expressed as
a percentage of maximal aggregation.14 Activation
was stopped by addition of Laemmli's buffer (125
mM Tris-HCl, 2% SDS, 5% glycerol and 0.003% bro-
mophenol blue) containing 2 mM orthovanadate
and 5 mM N-ethylmaleimide, and heated for 5 min-




Equal amounts of proteins in non-activated and
activated platelets were resolved by 8% SDS-poly-
acrylamide gel electrophoresis16 and transferred to
nitrocellulose membranes17 (BioRad, Hercules, CA,
USA). After blocking non-specific binding, Western-
blots were probed with horseradish peroxidase-con-
jugated anti-phosphotyrosine recombinant antibody
(RC20) (Transduction Laboratories, Lexington, KY,
USA). The excess of antibody was removed by exten-
sive washing and blots were developed by the
enhanced chemiluminiscence (ECL) method18
(Amersham Pharmacia Biotek, Essex, UK).
Results
Clinical evaluation, platelet function and
ultrastructural studies
Clinical characteristics, platelet counts, and
ultrastructural platelet granule analysis are
described in Table 1. Patient #1 was a female with
a severe decrease of dense granules (δ-SPD) and
absent release of ATP after stimulation of platelets
with 2mg/mL of collagen. Patient #2 was a man
with a severe decrease of α-granules (α-SPD), pre-
viously described as a case of gray platelet syn-
drome,19 with an associated hereditary deficiency
of plasma factor V. Patients #3 to 8 presented par-
tial forms of partial SPD (δ/α-SPD), including
dense- (5 cases) and α- (2 cases) granule defi-
ciencies. Some of the patients belonged to families
with other members affected.
Most patients had a moderate bleeding diathe-
sis, combined in some cases with thrombocytope-
nia. Bleeding time was prolonged in four cases,
including those patients with the most severe
defects. Aggregometry was normal or slightly
decreased in most cases, with the exception of
patient #1 who showed marked aggregometric
anomalies to the different agonists used.
Morphometric measurements on ultrastructural
images (Figure 1, Table 1) of patients’ platelets
showed different numbers of dense- or α-granule
per µm2 of platelet area, with respect to normal
individuals. Platelets from patient #1 contained
normal α-granules but the dense-granules were
decreased to 6% and revealed low electron densi-
ty. Platelets from patient #2 had normal numbers
of dense-granules without morphologic anomalies.
However, the platelets contained only scarce α-
granules with a marked reduction in size. A partial
deficiency of dense-granules was observed in
patients #3 to 6 and was sometimes associated
with morphologic anomalies in these granules,
such as fragmented dense cores or decreased elec-
tron density. A partial deficiency of α-granules was
observed in patients #7 and 8 which was associat-
ed, in the former, with very irregularly sized and
shaped α-granules and also many elongated forms.
As far as concerns the other ultrastructural fea-
tures analyzed, the main anomalies observed were
those affecting platelet size, and the following
intraplatelet structures: OCS, DTS, and lipid droplets
(Figure 1). All the patients except the one with δ-SPD
(patient #1) had variably larger platelets with an
increased amount of OCS. Some individual elements
of OCS were dilated, giving swiss-cheese platelet
images in the α-SPD patient, and in another with
δ/α-SPD (patient #4). DTS was also more developed
than normal in α-SPD, and in δ-SPD platelets
(patients #1, and 2), as well as in 2 patients with par-
tial SPD (patients #3, and 5). A lot of DTS complex-
es were observed in 3 of these patients (patients #1,
2, and 5). Finally, lipid droplets increased, to a vari-
able extent, in all the cases studied.
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Tyrosine phosphorylation after activation
of platelets with collagen and thrombin
Activation of platelet suspensions by purified
type I collagen and thrombin resulted in phospho-
rylation at tyrosine residues of multiple proteins,
including p160, p150, p125, p100, p97, p85, p72,
p66, p64, pp62, pp60, p58, p56 and p39 (Figure 2,
lanes 2 and 3).
Only a total deficiency in δ-granules resulted in
almost a total absence of signaling through tyro-
sine phosphorylation of proteins. Most of these
proteins observed in control platelets after activa-
tion were not detected in profiles corresponding to
platelet suspensions from patient #1, which were
activated with collagen or thrombin (Figure 2, lanes
5, and 6). Interestingly, platelets deficient in α-
granules, from patient #2, with gray platelet syn-
drome, responded significantly to collagen but not
to thrombin in terms of tyrosine phosphorylation of
proteins (Figure 2, lanes 8 and 9, respectively).
Activation of platelets from patients #3 to 8,
with partial SPD, did not result in significant dif-
ferences with respect to control samples. Profiles
were qualitatively identical to those in control
platelets, although intensity of phosphorylation at
tyrosine residues was only slightly decreased (Fig-
ure 2, lanes 11 and 12 are representative of the 6
different patients with partial SPD).
Discussion
Storage pool diseases are heterogeneous disor-
ders that cause a mild to moderate bleeding
diathesis. SPD are difficult to identify by the meth-
ods commonly used in the laboratory to assess
platelet function, due to the variability in response
that in many cases may be even normal. We report
studies on signaling through tyrosine phosphory-
lation of proteins. The studies were performed on
platelets with a total or partial defect of
intraplatelet granules, as demonstrated by ultra-
structural analysis and morphometric measure-
ments. Our present results indicate that signaling
through tyrosine phosphorylation of proteins is
absent only in those platelets with a total defect of
dense granules.
Absence of the second wave of aggregation with
ADP and epinephrine, and impaired response to
collagen are aggregation patterns that have been
commonly associated with SPD. However, it is cur-
rently accepted in the literature that SPD cannot be
excluded by simple aggregation studies, since
aggregation profiles are within the normal range in
a considerably high number of patients with
SPD.20,21 Our results using turbidimetric techniques
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Figure 1. Transmission electron microscopy images of
platelets from patients with (A) marked deficiency of dense-
granules, (B) marked deficiency of α-granules and (C) partial
α-granule deficiency. A: platelets containing a unique dense-
granule which shows an abnormal fragmented dense core
(arrow); a lipid droplet (LD) can also be seen; α−granules
and other intraplatelet structures appear normal (original
magnification 30,000 ×). B: only few, small-sized α-granules
can be observed in a unique platelet (arrowheads); dense-
granules are present in normal number and morphology
(arrows); several lipid droplets (LD), and a membranous com-
plex of dense tubular system can also be seen (MC); the
open canalicular system appears well developed in the major-
ity of platelets (original magnification 15,000 ×). C: the num-
bers of α-granules are decreased and the granules are irreg-
ularly sized and shaped; a normal dense granule can be seen
(arrow), and a dilated open canalicular system can also be
observed in some platelets. (original magnification 20,000
×).
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are in agreement with those from previous reports,
since aggregation responses were normal in most
of the patients and diminished only in one patient,
whose platelets exhibited a total absence of dense-
granules.
Careful ultrastructural and morphometric stud-
ies combined with morphologic observation pro-
vide useful diagnostic tools, especially in those cas-
es in which aggregation patterns are not confir-
matory of the disease.3,22 In partial forms of SPD
this methodology confirms the dense- or α-gran-
ule deficiency and can also quantify the degree of
the defect as well as detect structural anomalies in
the granules or in other platelet organelles. In the
present study, two patients were diagnosed as hav-
ing a severe SPD –one of dense-granules (δ-SPD)
and another of α-granules (α-SPD)–, and six could
be grouped as having partial forms of dense- or α-
granule deficiency (δ/α-SPD). Morphologic anom-
alies were found in the granules (Figure 1, Table 1),
but also in the development of OCS and DTS.
Increased lipid droplets were detected in platelets
from some of the patients included in the study.
The ultrastructural anomalies found in OCS and
DTS may represent structural defects that could
play a role in the platelet dysfunction present in
these patients. The presence of large platelets with
highly developed OCS and DTS, found in some of
the patients, could provide an extended membrane
reservoir facilitating the inside-out mediated
events. Whether these abnormal features are
causative, reactive, or could just partially compen-
sate the platelet dysfunction observed in SPD
platelets, is still unknown.
Although platelets with SPD are deficient in
granules, aggregating responses are within the
normal range in a high proportion of cases.20,21 In
the present study, we analyzed the signaling
processes occurring through tyrosine phosphoryla-
tion of proteins after activation of platelets from
patients with SPD. Although the group of patients
included in the study is rather heterogeneous, it is
representative of the nature of the disease, and the
results obtained are quite conclusive. Our results
indicate that a minimal amount of granules
ensures signaling through tyrosine kinases, since
phosphorylated proteins were detected in those
platelets with partial or combined granule defects,
and were both qualitatively and quantitatively
identical to those found in normal platelets. In fact,
in these patients, the aggregation profiles were
found to be normal. This was not the case for the
patients with severe absence of dense or α-gran-
ules, in whom the signaling mechanisms evaluat-
ed were absent or severely compromised.
Our present findings obtained from experiments
performed with the severe δ-SPD and the α-SPD
patients suggest that the substances contained in
the δ-granules, but not those in α-granules, are
essential to promote signaling through phospho-
tyrosine proteins in response to collagen and
thrombin. Dense granules are storage organelles
for adenine and guanine nucleotides, amines such
as serotonin and histamine, and bivalent cations.23
Table 1. Clinical characteristics, blood platelet counts, and ultrastructural platelet granule analysis.
Patients Age FP Clinical beeding Platelets Bleeding time (min) Platelet granules (%)
Sex EB MB ST × 109/L Dense α 
δ-SPD 1 57 F − ++ +++ ± 90 >20 6 * 70
α-SPD 2 29 M + + + + 60 >20 100 4 *
δ/α-SPD 
3 32 F + + + + 350 7.5 33 * 95
4 31 M − − ± − 110 11 50 * 71
5 44 F − + + − 160 6.5 18 * 95
6 20 F + ++ ++ − 320 9 53 75
7 44 F + + + + 85 16 98 65 *
8 18 M − − + − 200 6.5 90 61
δ-SPD: δ-storage-pool disease; α-SPD: α-storage-pool disease; δ/α-SPD: partial dense- or α-storage-pool disease; FP: familial presentation; EB: easy bruising;
MB: mucous bleeding; epistaxis, menorrhagia, bleeding gums; ST: surgical or traumatic bleeding; *: granules with dysmorphic features.
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The quantitative defect in signaling through tyro-
sine phosphorylation of proteins could be attrib-
uted to the absence of such substances. In this
regard, it should be considered that adenine
nucleotides are the main source of phosphate for
protein kinases.24 Therefore, the enzymatic process-
es of protein phosphorylation could be expected to
be abnormal. In addition, the tyrosine kinase Src
has been described to be present in the dense-
granules,25,26 apart from other locations,27,28 sug-
gesting its involvement in the secretion process.
We also evaluated signaling through tyrosine
phosphorylation in platelets from an α-SPD
patient, with gray platelet syndrome (GPS). This
rare disease is characterized by an almost com-
plete deficiency of platelet α-granules.29 The link
between the α-granule and functional defects has
not yet been explained. Some patients with GPS
have normal platelet aggregation, however, delayed
aggregation with epinephrine and reduced aggre-
gation with collagen and thrombin have been
described in other patients.30,31 Interestingly, in our
studies of a GPS patient, tyrosine phosphorylation
patterns in response to collagen were both quali-
tatively and quantitatively normal, although quan-
titatively inhibited in response to thrombin. This
finding could be in agreement with previous
reports on GPS, in which delayed platelet aggre-
gation with thrombin was described.32,33 In those
cases, the abnormal response to thrombin was
associated with a delay in calcium mobilization
and secretion, and abnormal calcium transport into
microsomes. The authors of those reports postu-
lated that, apart from the absence of α-granules,
Figure 2. Western blots showing tyrosine-phosphorylated proteins in platelets before (B) and after activation with purified type
I collagen (Col) and thrombin (T). Platelet suspensions were obtained from healthy volunteers (CONTROL), and from patients
with severe deficiency of dense- granules (δ-SPD), severe deficiency of α- granules (α-SPD), and partial deficiency of dense or
α-granules (δ/α-SPD).
platelets with GPS could have a specific defect of
thrombin receptor-mediated activation of phos-
pholipase C. In normal platelets, this event leads to
generation of second messengers such as IP3 and
increases of intraplatelet calcium, which play an
essential role in promoting both cytoskeletal orga-
nization and signaling through tyrosine phospho-
rylation of proteins. Defects at this level may com-
promise intraplatelet signaling.
Our present results are consistent with the con-
cept that even a minimal number of intraplatelet
granules guarantee signaling through phosphoty-
rosine proteins. In addition, our studies indicate
that phosphorylation of proteins at tyrosine
residues is highly dependent on substances con-
tained in the dense-granules and only moderately
dependent on those contained in α-granules.
Defects in signaling through tyrosine phosphoryla-
tion imply abnormal aggregating responses. Fur-
ther studies on tyrosine phosphorylation occurring
in platelets with SPD exposed to adhesive substra-
ta under flow will be useful to understand the
functional impact of these processes on platelet
function.
Contributions and Acknowledgments
GA was the principal investigator. She carried out
the experimental part of the study, and participat-
ed in the design, analysis and interpretation of the
results. MDR and GE were responsible for the con-
ception of the study and for its critical revision. We
thank AO for his contribution to the conception of
the discussion and critical revision of the study.
NPM was responsible for the handling and inter-
pretation of data and direct supervision. GA, MDR
and NPM wrote the manuscript. All the authors
approved the version sent to be published.
We thank Marcos Pino, and Angel Hernández for
technical assistance in the platelet function stud-
ies, and electron microscopy.
Funding
Support for these studies was provided by Gener-
alitat de Catalunya (2001 TDOC 00002 personal
grant for Gemma Arderiu, CIRIT SGR 383-2001, and
CIRIT 2000XT 00085), and Ministerio de Ciencia y
Tecnología (SAF2000-0041 and HF1999-0059).
Supported in part by grants from Fondo de Investi-
gaciones de la Seguridad Social (FIS 99/0110,
01/1512).
Disclosures
Conflict of interest: none.
Redundant publications: no substantial overlap-
ping with previous papers.
References
1. Lages B, Weiss HJ. Heterogeneous defects of platelet
secretion and responses to weak agonists in patients with
bleeding disorders. Br J Haematol 1988; 68:53-62.
2. Hayward CP. Inherited disorders of platelet α-granules.
Platelets 1997; 8:197-9.
3. Pujol-Moix N, Hernández A, Escolar G, Español I, Martínez-
Brotóns F, Mateo J. Platelet ultrastructural morphometry
for diagnosis of partial δ-storage pool disease in patients
with mild platelet dysfunction and/or thrombocytopenia of
unknown origin. Study of 24 cases. Haematologica 2000;
85:620-7.
4. Brass LF.The molecular basis for platelet activation. In:
Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silber-
stein LE, McGlave P, editors. Hematology. Basic principles
and practice. New York: Churchill Livingstone; 2000. p.
1841-50.
5. Harrison P, Cramer EM. Platelet α-granules. Blood Rev
1993; 7:52-62
6. Holmen H, Weiss HJ. Secretable storage pools in platelets.
Ann Rev Med 1979; 30:119-34.
7. Da Prada M, Richards JG, Kettler R. Amine storage vesicles
in platelets. In Gordon JL, editors. Platelets in biology and
pathology. Amsterdam: Elsevier/North Holland, 1981. p.
107-46.
8. Clark EA, Shattil SJ, Brugge JS. Regulation of protein tyro-
sine kinases in platelets. Trends Biochem Sci 1994;
19:464-9.
9. Rendu F, Maclouf J, Launay JM, Boinot C, Levy-Toledano
S, Tanzer J, et al. Hermansky-Pudlak platelets: further
studies on release reaction and protein phosphorylations.
Am J Hematol 1987; l25:165-74.
10. Rendu F, Marche P, Hovig T, Maclouf J, Lebret M, Tenza D,
et al. Abnormal phosphoinositide metabolism and protein
phosphorylation in platelets from a patient with the grey
platelet syndrome. Br J Haematol 1987; 67:199-206.
11. Pratt HL, Carroll RC, Jones JB, Lothrop CD Jr. Platelet
aggregation, storage pool deficiency, and protein phos-
phorylation in mice with Chediak-Higashi syndrome. Am
J Vet Res 1991; 52:945-50.
12. Suzuki T, Goryo M, Inanami O, Uetsuki J, Saito S, Kaketa
K, et al. Inhibition of collagen-induced platelet aggrega-
tion in Japanese black cattle with inherited platelet dis-
order, Chediak-Higashi syndrome. J Vet Med Sci 1996;
58:647-54.
13. Nieuwenhuis HK, Sixma JJ. Bleeding time measurements.
Methods Hematol 1983; 8:26-45.
14. Born GV. The aggregation of blood platelets by adenosine
diphosphate and its reversal. Nature 1962; 194:927-9.
15. Rao G, Escolar G, White JG. Epinephrine reverses the
inhibitors influence of aspirin on platelet-vessel wall inter-
actions. Thromb Res 1986; 44:65-74.
16. Laemmli UK. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature 1970;
227:680-5.
17. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer
of proteins from polyacrylamide gels to nitrocellulose
sheets: procedure and some applications. Proc Natl Acad
Sci USA 1979; 76:4350-4.
18. Cichowski K, McCormick F, Brugge JS. p21rasGAP associ-
ation with Fyn, Lyn, and Yes in thrombin-activated
platelets. J Biol Chem 1992; 267:5025-8.
19. Español I, Hernández A, Pujol-Moix N. The magic of
immersion oil: gray platelet syndrome. Haematologica
1998; 83:474-5.
20. Lages B, Weiss HJ. Biphasic aggregation responses to ADP
and epinephrine in some storage pool deficient platelets:
relationship to the role of endogenous ADP in platelet
aggregation and secretion. Thromb Haemost 1980;
635
haematologica vol. 87(6):june 2002
Defective signal transduction in storage pool disease
636
haematologica vol. 87(6):june 2002
G. Arderiu et al.
43:147-53.
21. Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a
prolonged bleeding time and normal aggregation tests
may have storage pool deficiency: studies on one hundred
six patients. Blood 1987; 70:620-3.
22. Witkop CJ, Krumwiede M, Sedano H, White JG. Reliability
of absent platelet dense bodies as a diagnostic criterion for
Hermansky-Pudlak syndrome. Am J Hematol 1987;
26:305-311.
23. Rendu F, Brohard-Bohn B. The platelet release reaction:
granules’ constituents, secretion and functions. Platelets
2001; 12:261-73.
24. Hardie DG, Hawley SA. AMP-activated protein kinase: the
energy charge hypothesis revisited. Bioessays 2001;
23:1112-9.
25. Rendu F, Lebret M, Danielian S, Fagard R, Fevy-Toledano
S, Fisher S. High pp60csrc level in human platelet dense
bodies. Blood 1989, 73:1545-51.
26. Rendu F, Martin Cramer E, Tenza D, Fisher S. Redistribu-
tion of granulophysin and SRC protein in normal and gray
platelets after activation. Platelets 1993; 4:167-74.
27. Ferrell JE Jr, Noble JA, Martin GS, Jacques YV, Bainton DF.
Intracellular localization of pp60c-src in human platelets.
Oncogene 1990; 5:1033-6.
28. Horvath AR, Muszbek L, Kellie S. Translocation of pp60c-
src to the cytoskeleton during platelet aggregation. Embo
J 1992; 11:855-61.
29. Hayward CP. Inherited disorders of platelet α-granules.
Platelets 1997; 8:197-209.
30. Raccuglia G. Gray platelet syndrome. A variety of qualita-
tive platelet disorder. Am J Med 1971; 51:818-28.
31. Gerrard JM, Phillips DR, Rao GH, Plow EF, Walz DA, Ross
R, et al. Biochemical studies of two patients with the grey
platelet syndrome. Selective deficiency of platelet α gran-
ules. J Clin Invest 1980; 66:102-9.
32. Srivastava PC, Powling MJ, Nokes TJ, Patrick AD, Dawes J,
Hardisty RM. Grey platelet syndrome: studies on plateletet
α-granules, lysosomes and defective response to throm-
bin. Br J Haematol 1987; 65:441-6.
33. Lages B, Sussmann II, Levine SP, Coletti, Weiss HJ. Platelet
alpha granule deficiency associated with decreased P-
selectin and selective impairment of thrombin-induced
activation in a new patient with gray platelet syndrome




This manuscript was peer-reviewed by two external ref-
erees and by Professor Carlo Balduini, Associate Editor.
The final decision to accept this paper for publication
was taken jointly by Professor Balduini and the Editors.
Manuscript received March 11, 2002; accepted April
26, 2002.
What is already known on this topic
Mechanisms of platelet activation in storage pool dis-
eases are poorly known since few patients have been
studied in this respect.
What this study adds
The present study of eight patients showed that a min-
imum amount of intraplatelet granules is required to
ensure signaling through tyrosine phosphorylation in
activated platelets.
Potential implications for clinical practice
Evaluation of signaling through tyrosine phosphorylation
after activation of platelets with collagen or thrombin
will help to determine the severity of the disease.
Carlo Balduini, Associate Editor
